3-[2-(二甲基氨基)乙基]-1-甲基-1H-吲哚-4-醇 | 1465-16-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-[2-(二甲基氨基)乙基]-1-甲基-1H-吲哚-4-醇
• 中文别名: 1-甲基香豆素
• 英文名称: 1-methylpsilocin
• 英文别名: 3-[2-(dimethylamino)ethyl]-1-methylindol-4-ol
• CAS: 1465-16-3
• 化学式: C₁₃H₁₈N₂O
• 分子量: 218.299
• InChiKey: MZZRFEIDRWKTKJ-UHFFFAOYSA-N

物化性质

• 熔点：
  >125°C (dec.)
• 沸点：
  383.6±32.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  28.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-[2-(二甲基氨基)乙基]-1-甲基-1H-吲哚-4-醇 在 palladium on activated charcoal 氢气 、 lithium diisopropyl amide 作用下， 生成 phosphoric acid mono-[3-(2-dimethylamino-ethyl)-1-methyl-indol-4-yl ester]
  参考文献：
  名称：

  SAR of psilocybin analogs: Discovery of a selective 5-HT2C agonist

  摘要：

  An SAR study of psilocybin and psilocin derivatives reveals that 1-methylpsilocin is a selective agonist at the h5-HT2C receptor. The corresponding phosphate derivative, 1-methylpsilocybin, shows efficacy in an animal model for obsessive-compulsive disorder, as does 4-fluoro-N,N-dimethyltryptamine. These results suggest a new area for development of novel 5-HT2C agonists with applications for drug discovery. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.104
• 作为产物：
  描述：

  4-苄氧基吲哚 在 palladium on activated charcoal lithium aluminium tetrahydride 、 氢气 、 sodium hydride 作用下， 生成 3-[2-(二甲基氨基)乙基]-1-甲基-1H-吲哚-4-醇
  参考文献：
  名称：

  SAR of psilocybin analogs: Discovery of a selective 5-HT2C agonist

  摘要：

  An SAR study of psilocybin and psilocin derivatives reveals that 1-methylpsilocin is a selective agonist at the h5-HT2C receptor. The corresponding phosphate derivative, 1-methylpsilocybin, shows efficacy in an animal model for obsessive-compulsive disorder, as does 4-fluoro-N,N-dimethyltryptamine. These results suggest a new area for development of novel 5-HT2C agonists with applications for drug discovery. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.104

文献信息

• [EN] 3-(2-(AMINOETHYL)-INDOL-4-OL DERIVATIVES, METHODS OF PREPARATION THEREOF, AND THE USE AS 5-HT2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE 3-(2-(AMINOÉTHYL)-INDOL-4-OL, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR 5-HT2
  申请人：BRIGHT MINDS BIOSCIENCES INC

  公开号：WO2021179091A1

  公开（公告）日：2021-09-16

  A compound of Formula I, which possesses 5-HT2A and/or 5-HT2c selective receptor activity, but lacks at least some of the undesirable characteristics of 5-HT2B-agonist related activities, is disclosed. Methods of preparing said compounds are also described. The compound of Formula I may be useful in the treatment of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders.

  公开了一种具有5-HT2A和/或5-HT2c选择性受体活性但缺乏至少一些不良特性的5-HT2B激动剂相关活性的化合物I的化合物。还描述了制备所述化合物的方法。化合物I的化合物可能在治疗抑郁症、酒精中毒、吸烟和可卡因成瘾、炎症、集群头痛、创伤后应激障碍、癫痫和其他中枢神经系统疾病方面有用。
• Abwandlungsprodukte von Psilocybin und Psilocin. 2. Mitteilung über synthetische Indolverbindungen
  作者：F. Troxler、F. Seemann、A. Hofmann

  DOI：10.1002/hlca.19590420638

  日期：——

  psilocin derivatives with other substitution at the ω-nitrogen; derivatives of II substituted at the indole nitrogen; psilocin derivatives with one additional methylene group in the side-chain or with a methyl-substituted or hydroxylated side-chain; phosphoric acid esters of some derivatives of II; esters of II with organic carbonic and sulfonic acids, with methylcarbaminic and with sulfuric acid; position

  对天然精神药物psilocybin（I）和psilocin（11）的分子结构进行了各种修饰，以了解这组物质的结构与精神作用之间的关系。描述了四个异构体羟基葡糖胺的I和II的位置异构体的合成和性质，其中I和II在5、6或7位具有磷酰氧基或羟基，以及一系列其他的4-羟基吲哚衍生物其中II的结构被系统地修饰，即在ω-氮处具有其他取代的psilocin衍生物；在吲哚氮上取代的II的衍生物；在侧链上具有一个另外的亚甲基或具有甲基取代的或羟基化的侧链的psilocin衍生物；II的一些衍生物的磷酸酯；II与有机碳酸和磺酸，甲基氨基甲酸酯和硫酸的酯；psilocin的位置异构体，其二甲基氨基乙基侧链位于1或2位。
• INDOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Sard Howard

  公开号：US20090318527A1

  公开（公告）日：2009-12-24

  Novel indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.

  本发明涉及新的吲哚化合物。本发明还公开了使用这些化合物治疗人类和动物疾病的方法，这些化合物的制药组合物以及包括这些化合物的试剂盒。
• COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Elder Amy

  公开号：US20110144090A1

  公开（公告）日：2011-06-16

  Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.

  揭示了吲哚化合物。还揭示了使用该化合物治疗人类和动物疾病的方法，该化合物的药物组成以及包括该化合物的试剂盒。
• TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
  申请人：STAMETS Paul Edward

  公开号：US20210069170A1

  公开（公告）日：2021-03-11

  Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum ) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica , or Cannabis ruderalis , optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.